FDA Approves First-Ever Treatment for Rare MCT8 Deficiency, and Akron Family Celebrates Like the RubberDucks Won It All
The FDA approved the first-ever treatment for a rare genetic disease — and one Akron family refreshed the announcement page so many times their Wi-Fi gave up.
What actually happened
The U.S. Food and Drug Administration approved Emcitate (tiratricol) tablets for oral suspension on September 28, 2026, to treat peripheral thyrotoxicosis — excess thyroid hormone levels in the blood that cause symptoms such as rapid heart rate, increased blood pressure, and adverse effects on metabolism — in patients with MCT8 deficiency, also known as Allan-Herndon-Dudley syndrome. Emcitate is the first therapy approved by the FDA to treat symptoms of this very rare, devastating genetic disease. 'Until now, patients living with MCT8 deficiency and their families had no FDA-approved treatment option,' said Marina Zemskova, M.D., Deputy Director of the Division of General Endocrinology in the FDA's Center for Drug Evaluation and Research.
MCT8 deficiency is a rare genetic disorder that primarily affects males, caused by a faulty gene that provides instructions for making the MCT8 transporter, a critical protein responsible for carrying thyroid hormone into the brain. Because thyroid hormone cannot cross the blood-brain barrier without the MCT8 transporter, the brain receives too little of the hormone while excessive levels build up in the bloodstream. Many patients experience a range of debilitating effects, including the inability to walk or sit independently, absent or severely limited speech, intellectual disability, feeding difficulties, and chronic stress on the heart and metabolism. The drug's active ingredient, tiratricol, can enter cells on its own without relying on the broken transporter, leading to a decrease in the elevated blood thyroid hormone levels.
The effectiveness of Emcitate was evaluated in two clinical studies in patients ranging in age from infants to adults, including an international, multi-center, randomized, placebo-controlled trial (NCT05579327) and a longer-term open-label study. Across both studies, patients treated with Emcitate had reductions in excess thyroid hormone levels in the bloodstream and improvements in cardiovascular and metabolic symptoms such as systolic blood pressure and heart rate. Emcitate is taken once daily as a liquid suspension, either by mouth or through a feeding tube, and its most common side effects were diarrhea, vomiting, rash, and excessive sweating. The drug was granted Orphan Drug, Rare Pediatric Disease, Fast Track, and Breakthrough Therapy designations as well as Priority Review, and the approval was granted to Egetis Therapeutics US Inc.

Meanwhile, in Ohio
AKRON, Ohio — Mark and Sarah Kowalski got the news the way most Akron parents get big news: in the pickup line, on a phone with 4% battery, while their son Leo, 9, explained from the back seat why the RubberDucks should trade for a better closer. The FDA had approved Emcitate, the first treatment ever cleared for MCT8 deficiency, the rare genetic condition Leo has lived with since he was a baby. Mark read the announcement twice, called Sarah, and then sat in the car for a full minute with the engine running and the radio off, which Sarah later described as 'the quietest he has ever been, including our wedding.'
Leo's MCT8 deficiency means his body cannot move thyroid hormone into his brain properly, leaving too little where it is needed and too much building up in his blood — a combination that has meant feeding tubes, therapy appointments, and more trips to Akron Children's Hospital than the family can count. The new drug, a once-a-day liquid that can go through a feeding tube, works by slipping into cells without the broken transporter that causes the problem. 'For nine years, every doctor's visit has basically been a lesson in what we can't fix yet,' Sarah said. 'Now there's a sentence that starts with the word treatment. I printed the announcement and put it on the fridge next to Leo's school picture. It is the only thing on that fridge that isn't a drawing of a dinosaur.'
The family celebrated the way Akron celebrates anything: Swensons drive-in burgers in the car, with Leo ordering for the whole table in the exact voice he uses to order at every restaurant in Summit County, which is to say, very loudly and with total confidence. Mark has already done the math on the drive to the pharmacy, twice, and has a group chat going with three other MCT8 families across Ohio that has not stopped buzzing since Monday. 'Somebody in Columbus asked if we were going to throw a party,' Mark said. 'I told them we already did. It was in a parked car outside Swensons, and Leo ate two burgers, and honestly, that is the best party this family has ever thrown.'

“I refreshed the FDA page so many times our router filed a complaint. Then I read the words 'first therapy approved' out loud and my wife started crying into the pierogies.”
— Mark Kowalski, Akron
“Leo has waited nine years for somebody to say the words 'there is a treatment now.' I called Akron Children's before I even finished reading the announcement. The nurse said, 'Sarah, we saw it too.'”
— Sarah Kowalski, Akron